Table 2.
Baseline characteristics of the pilot study population, according to the assigned treatment group 1.
| Intervention (n= 7) |
Control (n= 8) |
|
|---|---|---|
| Age (years) | 38 ± 10 | 41 ±10 |
| Sex (n) Women/Men | 7/0 | 7/1 |
| Weight (kg) | 112.9 ±19.5 | 135.9 ±23.2 |
| BMI (kg/m2) | 44.7 ± 4.5 | 48.5 ± 6.7 |
| Waist circumference (cm) | 130.4 ± 12.1 | 138.0 ± 11.4 |
| FM (%) | 47.7 ± 4.1 | 52.4 ± 3.8 |
| PA (°) | 6.6 ± 0.6 | 6.0 ± 0.6 |
| 6MWD (m) | 447.1 ± 83.5 | 433.5 ± 37.4 |
| 6MWD (%) | 86.1 ± 16.1 | 90.8 ± 12.5 |
| HGS Right Hand (kg) | 24.0 ± 7.7 | 29.7 ± 9.1 |
| HGS Left Hand (kg) | 24.1 ± 2.6 | 26.2 ± 8.6 |
| IPAQ 2 | ||
| Low | 1 (20) | 1 (16.6) |
| Moderate | 2 (40) | 5 (83.3) |
| High | 2 (40) | 0 (0) |
| NA | 2 | 2 |
| HbA1c (%) | 5.9 ± 1.7 | 5.5 ± 0.4 |
| Diabetes mellitus 2 | 3 (42.9%) | 1 (12.5%) |
| Hypertension 2 | 3 (42.9%) | 2 (25.0%) |
| HDL-cholesterol (mg/dL) | 47 ± 10 | 41 ± 7 |
| LDL-cholesterol (mg/dL) | 114 ± 46 | 105 ± 25 |
| Dyslipidaemia 2 | 2 (28.6%) | 2 (25%) |
| NAFLD 2 | 1 (14.3%) | 2 (25%) |
| Ferriman-Gallwey Score | 0 ± 1 | 1 ± 1 |
| Infertility 2 | 3 (42.9) | 2 (25%) |
| Chronic venous insufficiency 2 | 2 (28.6) | 2 (25%) |
| OSA 2 | 3 (75) | 3 (50) |
| Function limiting osteoarthritis 2 | 2 (28.6) | 4 (50%) |
| Gastroesophageal reflux/Hiatal hernia 2 | 1 (14.3) | 1 (12.5%) |
| Bronchial asthma 2 | 2 (28.6) | 3 (37.5%) |
| Intracranial hypertension 2 | 1 (14.3) | 0 (0%) |
| EQ-5D-5L score | 57 ± 23 | 47 ± 24 |
| MEDAS | ||
| High | 1 (20) | 7 (100) |
| Low | 4 (80) | 0 (0) |
| NA | 2 | 1 |
| EDI-3 score | 168 ± 27 | 198 ± 49 |
| HADS score | 16 (7) | 16 (5) |
| HADS 2 | ||
| Normal | 3 (60) | 1 (20) |
| Probable case | 2 (40) | 5 (80) |
| NA | 2 | 2 |
1 Plus-minus values are the means ± SD. 2 Values are n (percentage of sample). BMI: body mass index; NA: not available; FM%: (fat mass percentage); PA: phase angle; 6MWD: six-minute walk distance; 6MWD: percentage of theoretical six-minute walk distance; HGS: handgrip strength; IPAQ: International Physical Activity Questionnaire; NAFLD: nonalcoholic fatty liver disease; OSA: Obstructive Sleep Apnea; EQ-5D-5L: EuroQol-5D-5L; MEDAS: Adherence to the Mediterranean Diet Adherence Screener; EDI-3: Eating Disorder Inventory; HADS: Hospital Anxiety and Depression Scale.